Free Trial

Veracyte (VCYT) Competitors

Veracyte logo
$31.05 -2.64 (-7.84%)
Closing price 03/26/2025 04:00 PM Eastern
Extended Trading
$31.13 +0.08 (+0.26%)
As of 03/26/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VCYT vs. HIMS, OPCH, GH, RDNT, SHC, SGRY, BTSG, PRVA, CON, and WGS

Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), Surgery Partners (SGRY), BrightSpring Health Services (BTSG), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and GeneDx (WGS). These companies are all part of the "healthcare" industry.

Veracyte vs.

Hims & Hers Health (NYSE:HIMS) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

Hims & Hers Health presently has a consensus target price of $37.31, indicating a potential upside of 11.72%. Veracyte has a consensus target price of $43.40, indicating a potential upside of 39.77%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hims & Hers Health
2 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.27
Veracyte
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hims & Hers Health$1.48B5.02-$23.55M$0.5461.84
Veracyte$445.76M5.43-$74.40M$0.30103.50

In the previous week, Hims & Hers Health had 8 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Hims & Hers Health and 18 mentions for Veracyte. Hims & Hers Health's average media sentiment score of 1.08 beat Veracyte's score of 0.96 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hims & Hers Health
18 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Veracyte
8 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Hims & Hers Health8.19% 10.97% 8.29%
Veracyte -2.18%3.02%2.80%

Veracyte received 406 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.01% of users gave Veracyte an outperform vote while only 37.07% of users gave Hims & Hers Health an outperform vote.

CompanyUnderperformOutperform
Hims & Hers HealthOutperform Votes
43
37.07%
Underperform Votes
73
62.93%
VeracyteOutperform Votes
449
73.01%
Underperform Votes
166
26.99%

Hims & Hers Health has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

63.5% of Hims & Hers Health shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by insiders. Comparatively, 1.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Hims & Hers Health beats Veracyte on 11 of the 18 factors compared between the two stocks.

Remove Ads
Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

MetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$2.42B$2.89B$5.62B$8.13B
Dividend YieldN/A21.70%4.56%4.00%
P/E Ratio-207.0013.2424.5319.09
Price / Sales5.43201.14385.7894.71
Price / Cash442.2957.5638.1634.64
Price / Book2.174.586.934.36
Net Income-$74.40M-$22.21M$3.20B$247.23M
7 Day Performance-2.48%-1.66%-2.20%-0.34%
1 Month Performance-8.24%-2.50%3.13%-3.60%
1 Year Performance42.96%0.93%10.99%2.01%

Veracyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
4.5691 of 5 stars
$31.05
-7.8%
$43.40
+39.8%
+46.7%$2.42B$445.76M-207.00790Analyst Forecast
HIMS
Hims & Hers Health
3.2728 of 5 stars
$34.68
+4.6%
$37.23
+7.4%
+111.2%$7.70B$1.48B78.821,046Positive News
OPCH
Option Care Health
3.9556 of 5 stars
$33.89
+3.8%
$33.00
-2.6%
+6.6%$5.60B$5.00B28.485,600Positive News
GH
Guardant Health
3.7107 of 5 stars
$42.90
+0.0%
$48.40
+12.8%
+159.1%$5.29B$739.02M-12.051,790Analyst Forecast
News Coverage
RDNT
RadNet
3.8633 of 5 stars
$49.02
+5.3%
$76.75
+56.6%
+5.0%$3.63B$1.83B-700.198,970Analyst Forecast
High Trading Volume
SHC
Sotera Health
2.8528 of 5 stars
$11.93
+2.9%
$15.92
+33.4%
+1.4%$3.38B$1.10B47.723,000Positive News
SGRY
Surgery Partners
2.3252 of 5 stars
$24.40
+3.4%
$36.63
+50.1%
-17.7%$3.11B$3.11B-50.8313,500Analyst Forecast
BTSG
BrightSpring Health Services
2.548 of 5 stars
$17.45
+0.2%
$21.67
+24.2%
+87.3%$3.05B$11.27B-67.1235,000
PRVA
Privia Health Group
3.6513 of 5 stars
$23.24
-2.1%
$26.67
+14.7%
+20.6%$2.80B$1.74B232.421,102Positive News
CON
Concentra Group Holdings Parent
N/A$21.04
+1.2%
$28.38
+34.8%
N/A$2.68B$1.90B13.9411,000Positive News
WGS
GeneDx
2.3599 of 5 stars
$94.46
-4.1%
$72.33
-23.4%
+1,003.4%$2.65B$305.45M-48.191,200Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:VCYT) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners